(NVO) Novo Nordisk - Ratings and Ratios
Insulin, Obesity Medication, Hemophilia Drugs, Growth Hormone, Diabetes Pens
NVO EPS (Earnings per Share)
NVO Revenue
Description: NVO Novo Nordisk September 24, 2025
Novo Nordisk A/S (NYSE:NVO) is a Denmark-based, globally-distributed pharmaceutical company that develops, manufactures, and markets medicines across Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America and other regions.
The firm operates two primary segments: (1) Diabetes & Obesity Care, which supplies insulin, GLP-1 agonists, and emerging cardiovascular and obesity therapies; and (2) Rare Disease, which focuses on treatments for rare blood and endocrine disorders as well as hormone-replacement products. Ancillary offerings include insulin and growth-hormone pens, injection needles, and digital tools such as smart insulin pens and the Dose Check dose-guidance app.
Strategic collaborations augment its pipeline: a UNICEF partnership targets childhood obesity, while a joint venture with Valo Health aims to discover novel cardiometabolic candidates. Novo Nordisk was founded in 1923 and remains headquartered in Bagsværd, Denmark.
Key recent metrics (FY 2023): revenue of DKK 141 billion (≈ US$ 20 billion), a 12 % YoY increase driven largely by growth in GLP-1 products; R&D spend of DKK 15 billion (≈ 2 % of sales), reflecting continued investment in next-generation obesity and rare-disease pipelines; and an operating margin of 31 %, well above the GICS Pharmaceuticals average of 22 %. The diabetes market’s secular tailwinds-rising global prevalence (≈ 537 million adults) and expanding indications for GLP-1 agents-support Novo Nordisk’s revenue outlook, while pricing pressure in mature insulin markets remains a risk factor.
For a deeper quantitative assessment of Novo Nordisk’s valuation metrics, the ValueRay platform offers a granular, data-driven view worth exploring.
NVO Stock Overview
| Market Cap in USD | 237,019m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1982-01-04 |
NVO Stock Ratings
| Growth Rating | -20.1% |
| Fundamental | 87.9% |
| Dividend Rating | 64.3% |
| Return 12m vs S&P 500 | -60.2% |
| Analyst Rating | 3.50 of 5 |
NVO Dividends
| Dividend Yield 12m | 3.24% |
| Yield on Cost 5y | 5.75% |
| Annual Growth 5y | 21.92% |
| Payout Consistency | 96.1% |
| Payout Ratio | 6.8% |
NVO Growth Ratios
| Growth Correlation 3m | 46.5% |
| Growth Correlation 12m | -89.6% |
| Growth Correlation 5y | 75.2% |
| CAGR 5y | 0.97% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.01 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.05 |
| Sharpe Ratio 12m | -0.77 |
| Alpha | -62.50 |
| Beta | 0.331 |
| Volatility | 40.62% |
| Current Volume | 12147.3k |
| Average Volume 20d | 10182.1k |
| Stop Loss | 50.4 (-3.2%) |
| Signal | -0.81 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (111.07b TTM) > 0 and > 6% of Revenue (6% = 18.72b TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA -5.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -14.37% (prev -4.03%; Δ -10.33pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.25 (>3.0%) and CFO 121.53b > Net Income 111.07b (YES >=105%, WARN >=100%) |
| Net Debt (80.83b) to EBITDA (171.27b) ratio: 0.47 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (4.45b) change vs 12m ago -0.42% (target <= -2.0% for YES) |
| Gross Margin 83.95% (prev 84.53%; Δ -0.58pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 73.26% (prev 69.85%; Δ 3.42pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 19.49 (EBITDA TTM 171.27b / Interest Expense TTM 8.14b) >= 6 (WARN >= 3) |
Altman Z'' 3.57
| (A) -0.09 = (Total Current Assets 162.71b - Total Current Liabilities 207.52b) / Total Assets 482.15b |
| (B) 0.34 = Retained Earnings (Balance) 164.45b / Total Assets 482.15b |
| (C) 0.37 = EBIT TTM 158.76b / Avg Total Assets 425.77b |
| (D) 0.54 = Book Value of Equity 168.07b / Total Liabilities 314.09b |
| Total Rating: 3.57 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 87.88
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 3.87% = 1.94 |
| 3. FCF Margin 19.87% = 4.97 |
| 4. Debt/Equity 0.59 = 2.33 |
| 5. Debt/Ebitda 0.47 = 2.33 |
| 6. ROIC - WACC (= 45.85)% = 12.50 |
| 7. RoE 77.86% = 2.50 |
| 8. Rev. Trend 96.27% = 7.22 |
| 9. EPS Trend 51.83% = 2.59 |
What is the price of NVO shares?
Over the past week, the price has changed by -4.98%, over one month by -6.22%, over three months by -23.71% and over the past year by -52.40%.
Is Novo Nordisk a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NVO is around 45.01 USD . This means that NVO is currently overvalued and has a potential downside of -13.53%.
Is NVO a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 5
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the NVO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 62.3 | 19.8% |
| Analysts Target Price | 62.3 | 19.8% |
| ValueRay Target Price | 49.5 | -4.9% |
NVO Fundamental Data Overview October 25, 2025
P/E Trailing = 13.7191
P/E Forward = 14.0845
P/S = 0.7598
P/B = 9.8798
P/EG = 1.4816
Beta = 0.331
Revenue TTM = 311.94b DKK
EBIT TTM = 158.76b DKK
EBITDA TTM = 171.27b DKK
Long Term Debt = 87.31b DKK (from longTermDebt, last quarter)
Short Term Debt = 11.96b DKK (from shortTermDebt, last quarter)
Debt = 99.27b DKK (from shortLongTermDebtTotal, last quarter)
Net Debt = 80.83b DKK (from netDebt column, last quarter)
Enterprise Value = 1600.29b DKK (1519.96b + Debt 99.27b - CCE 18.93b)
Interest Coverage Ratio = 19.49 (Ebit TTM 158.76b / Interest Expense TTM 8.14b)
FCF Yield = 3.87% (FCF TTM 61.99b / Enterprise Value 1600.29b)
FCF Margin = 19.87% (FCF TTM 61.99b / Revenue TTM 311.94b)
Net Margin = 35.61% (Net Income TTM 111.07b / Revenue TTM 311.94b)
Gross Margin = 83.95% ((Revenue TTM 311.94b - Cost of Revenue TTM 50.07b) / Revenue TTM)
Gross Margin QoQ = 83.29% (prev 83.49%)
Tobins Q-Ratio = 3.32 (Enterprise Value 1600.29b / Total Assets 482.15b)
Interest Expense / Debt = 4.99% (Interest Expense 4.96b / Debt 99.27b)
Taxrate = 21.60% (7.30b / 33.80b)
NOPAT = 124.47b (EBIT 158.76b * (1 - 21.60%))
Current Ratio = 0.78 (Total Current Assets 162.71b / Total Current Liabilities 207.52b)
Debt / Equity = 0.59 (Debt 99.27b / totalStockholderEquity, last quarter 168.07b)
Debt / EBITDA = 0.47 (Net Debt 80.83b / EBITDA 171.27b)
Debt / FCF = 1.30 (Net Debt 80.83b / FCF TTM 61.99b)
Total Stockholder Equity = 142.65b (last 4 quarters mean from totalStockholderEquity)
RoA = 23.04% (Net Income 111.07b / Total Assets 482.15b)
RoE = 77.86% (Net Income TTM 111.07b / Total Stockholder Equity 142.65b)
RoCE = 69.04% (EBIT 158.76b / Capital Employed (Equity 142.65b + L.T.Debt 87.31b))
RoIC = 52.88% (NOPAT 124.47b / Invested Capital 235.40b)
WACC = 7.03% (E(1519.96b)/V(1619.23b) * Re(7.23%) + D(99.27b)/V(1619.23b) * Rd(4.99%) * (1-Tc(0.22)))
Discount Rate = 7.23% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.34%
[DCF Debug] Terminal Value 79.57% ; FCFE base≈63.60b ; Y1≈69.73b ; Y5≈88.93b
Fair Price DCF = 459.5 (DCF Value 1547.72b / Shares Outstanding 3.37b; 5y FCF grow 11.02% → 3.0% )
EPS Correlation: 51.83 | EPS CAGR: -49.91% | SUE: -4.0 | # QB: 0
Revenue Correlation: 96.27 | Revenue CAGR: 20.94% | SUE: -0.00 | # QB: 0
Additional Sources for NVO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle